Abstract 501: Discovery of BPI-460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrationsHongling Shen, Jiabing Wang, Di Zhu et al.|Cancer Research|2023Cited by 11
Abstract 495: Discovery of BPI-221351, a potent, selective, orally available, and brain penetrating dual inhibitor of mutant IDH1/2Hongling Shen, Jia‐Bing Wang, Xiaofeng Xu et al.|Cancer Research|2023Cited by 2
Abstract 1751: BPI-23314: A novel orally bioavailable small molecular BET inhibitor with target protein degradation activityJing Guo, Jiabing Wang, Yan Xu et al.|Cancer Research|2020Cited by 0